FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913859329> ?p ?o ?g. }

• W2913859329 endingPage "74.e3" @default.
• W2913859329 startingPage "64" @default.
• W2913859329 abstract "Background and Aims Self-expanding metal stents (SEMSs) when deployed across the gastroesophageal junction (GEJ) can lead to reflux with risks of aspiration. A SEMS with a tricuspid antireflux valve (SEMS-V) was designed to address this issue. The aim of this study was to evaluate the efficacy and safety of this stent. Methods A phase III, multicenter, prospective, noninferiority, randomized controlled trial was conducted on patients with malignant dysphagia requiring SEMSs to be placed across the GEJ. Patients were randomized to receive SEMSs with no valve (SEMS-NV) or SEMS-V. Postdeployment dysphagia score at 2 weeks and Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) questionnaire score at 4 weeks were measured. Patients were followed for 24 weeks. Results Sixty patients were randomized (SEMS-NV: 30 patients, mean age 67 ± 13 years; SEMS-V: 30 patients, mean age 65 ± 12 years). Baseline dysphagia scores (SEMS-NV, 2.5 ± .8; SEMS-V, 2.5 ± .8) and GERD-HRQL scores (SEMS-NV, 11.1 ± 8.2; SEMS-V, 12.8 ± 8.3) were similar. All SEMSs were successfully deployed. A similar proportion of patients in both arms improved from advanced dysphagia to moderate to no dysphagia (SEMS-NV, 71%; SEMS-V, 74%; 95% confidence interval, 1.93 [–17.8 to 21.7]). The dysphagia scores were also similar across all follow-up time points. Mean GERD-HRQL scores improved by 7.4 ± 10.2 points in the SEMS-V arm and by 5.2 ± 8.3 in the SEMS-NV group (P = .96). The GERD-HRQL scores were similar across all follow-up time points. Aspiration pneumonia occurred in 3.3% in the SEMS-NV arm and 6.9% in the SEMS-V arm (P = .61). Migration rates were similar (SEMS-NV, 33%; SEMS-V, 48%; P = .29). Two SEMS-V spontaneously fractured. There was no perforation, food impaction, or stent-related death in either group. Conclusions The SEMS-V was equally effective in relieving dysphagia as compared with the SEMS-NV. Presence of the valve did not increase the risks of adverse events. GERD symptom scores were similar between the 2 stents, implying either that the valve was not effective or that all patients on proton pump inhibitors could have masked the symptoms of GERD. Studies with objective evaluations such as fluoroscopy and/or pH/impedance are recommended. (Clinical trial registration number: NCT02159898.) Self-expanding metal stents (SEMSs) when deployed across the gastroesophageal junction (GEJ) can lead to reflux with risks of aspiration. A SEMS with a tricuspid antireflux valve (SEMS-V) was designed to address this issue. The aim of this study was to evaluate the efficacy and safety of this stent. A phase III, multicenter, prospective, noninferiority, randomized controlled trial was conducted on patients with malignant dysphagia requiring SEMSs to be placed across the GEJ. Patients were randomized to receive SEMSs with no valve (SEMS-NV) or SEMS-V. Postdeployment dysphagia score at 2 weeks and Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) questionnaire score at 4 weeks were measured. Patients were followed for 24 weeks. Sixty patients were randomized (SEMS-NV: 30 patients, mean age 67 ± 13 years; SEMS-V: 30 patients, mean age 65 ± 12 years). Baseline dysphagia scores (SEMS-NV, 2.5 ± .8; SEMS-V, 2.5 ± .8) and GERD-HRQL scores (SEMS-NV, 11.1 ± 8.2; SEMS-V, 12.8 ± 8.3) were similar. All SEMSs were successfully deployed. A similar proportion of patients in both arms improved from advanced dysphagia to moderate to no dysphagia (SEMS-NV, 71%; SEMS-V, 74%; 95% confidence interval, 1.93 [–17.8 to 21.7]). The dysphagia scores were also similar across all follow-up time points. Mean GERD-HRQL scores improved by 7.4 ± 10.2 points in the SEMS-V arm and by 5.2 ± 8.3 in the SEMS-NV group (P = .96). The GERD-HRQL scores were similar across all follow-up time points. Aspiration pneumonia occurred in 3.3% in the SEMS-NV arm and 6.9% in the SEMS-V arm (P = .61). Migration rates were similar (SEMS-NV, 33%; SEMS-V, 48%; P = .29). Two SEMS-V spontaneously fractured. There was no perforation, food impaction, or stent-related death in either group. The SEMS-V was equally effective in relieving dysphagia as compared with the SEMS-NV. Presence of the valve did not increase the risks of adverse events. GERD symptom scores were similar between the 2 stents, implying either that the valve was not effective or that all patients on proton pump inhibitors could have masked the symptoms of GERD. Studies with objective evaluations such as fluoroscopy and/or pH/impedance are recommended. (Clinical trial registration number: NCT02159898.)" @default.
• W2913859329 created "2019-02-21" @default.
• W2913859329 creator A5000080146 @default.
• W2913859329 creator A5001851791 @default.
• W2913859329 creator A5007593763 @default.
• W2913859329 creator A5018963112 @default.
• W2913859329 creator A5021880991 @default.
• W2913859329 creator A5030885577 @default.
• W2913859329 creator A5036364640 @default.
• W2913859329 creator A5038517805 @default.
• W2913859329 creator A5044534704 @default.
• W2913859329 creator A5044819265 @default.
• W2913859329 creator A5046731352 @default.
• W2913859329 creator A5060651496 @default.
• W2913859329 creator A5068377611 @default.
• W2913859329 creator A5071605841 @default.
• W2913859329 creator A5076475322 @default.
• W2913859329 creator A5084792796 @default.
• W2913859329 creator A5086709717 @default.
• W2913859329 creator A5090493677 @default.
• W2913859329 date "2019-07-01" @default.
• W2913859329 modified "2023-10-01" @default.
• W2913859329 title "A phase III, multicenter, prospective, single-blinded, noninferiority, randomized controlled trial on the performance of a novel esophageal stent with an antireflux valve (with video)" @default.
• W2913859329 cites W1968195485 @default.
• W2913859329 cites W1979672494 @default.
• W2913859329 cites W1983975172 @default.
• W2913859329 cites W1988246670 @default.
• W2913859329 cites W1991547025 @default.
• W2913859329 cites W1998204648 @default.
• W2913859329 cites W2015367105 @default.
• W2913859329 cites W2018595366 @default.
• W2913859329 cites W2023110997 @default.
• W2913859329 cites W2023906630 @default.
• W2913859329 cites W2033418244 @default.
• W2913859329 cites W2034007606 @default.
• W2913859329 cites W2038526643 @default.
• W2913859329 cites W2046032619 @default.
• W2913859329 cites W2052209432 @default.
• W2913859329 cites W2071146527 @default.
• W2913859329 cites W2096162844 @default.
• W2913859329 cites W2098918943 @default.
• W2913859329 cites W2102441110 @default.
• W2913859329 cites W2140357802 @default.
• W2913859329 cites W2158542739 @default.
• W2913859329 cites W2166058394 @default.
• W2913859329 cites W2166568422 @default.
• W2913859329 cites W2314203483 @default.
• W2913859329 cites W2331644271 @default.
• W2913859329 cites W2462624035 @default.
• W2913859329 cites W2470427585 @default.
• W2913859329 cites W2568350133 @default.
• W2913859329 cites W2737970188 @default.
• W2913859329 cites W2795425643 @default.
• W2913859329 cites W2808524416 @default.
• W2913859329 cites W4313371600 @default.
• W2913859329 doi "https://doi.org/10.1016/j.gie.2019.01.013" @default.
• W2913859329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30684601" @default.
• W2913859329 hasPublicationYear "2019" @default.
• W2913859329 type Work @default.
• W2913859329 sameAs 2913859329 @default.
• W2913859329 citedByCount "10" @default.
• W2913859329 countsByYear W29138593292019 @default.
• W2913859329 countsByYear W29138593292020 @default.
• W2913859329 countsByYear W29138593292021 @default.
• W2913859329 countsByYear W29138593292022 @default.
• W2913859329 countsByYear W29138593292023 @default.
• W2913859329 crossrefType "journal-article" @default.
• W2913859329 hasAuthorship W2913859329A5000080146 @default.
• W2913859329 hasAuthorship W2913859329A5001851791 @default.
• W2913859329 hasAuthorship W2913859329A5007593763 @default.
• W2913859329 hasAuthorship W2913859329A5018963112 @default.
• W2913859329 hasAuthorship W2913859329A5021880991 @default.
• W2913859329 hasAuthorship W2913859329A5030885577 @default.
• W2913859329 hasAuthorship W2913859329A5036364640 @default.
• W2913859329 hasAuthorship W2913859329A5038517805 @default.
• W2913859329 hasAuthorship W2913859329A5044534704 @default.
• W2913859329 hasAuthorship W2913859329A5044819265 @default.
• W2913859329 hasAuthorship W2913859329A5046731352 @default.
• W2913859329 hasAuthorship W2913859329A5060651496 @default.
• W2913859329 hasAuthorship W2913859329A5068377611 @default.
• W2913859329 hasAuthorship W2913859329A5071605841 @default.
• W2913859329 hasAuthorship W2913859329A5076475322 @default.
• W2913859329 hasAuthorship W2913859329A5084792796 @default.
• W2913859329 hasAuthorship W2913859329A5086709717 @default.
• W2913859329 hasAuthorship W2913859329A5090493677 @default.
• W2913859329 hasConcept C126322002 @default.
• W2913859329 hasConcept C141071460 @default.
• W2913859329 hasConcept C168563851 @default.
• W2913859329 hasConcept C188816634 @default.
• W2913859329 hasConcept C2775965419 @default.
• W2913859329 hasConcept C2776204476 @default.
• W2913859329 hasConcept C2777014526 @default.
• W2913859329 hasConcept C2777819096 @default.
• W2913859329 hasConcept C2778583881 @default.
• W2913859329 hasConcept C2779134260 @default.
• W2913859329 hasConcept C2780323790 @default.
• W2913859329 hasConcept C2780596822 @default.
• W2913859329 hasConcept C2992435398 @default.

• next